Iris (anatomy)

PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases

Retrieved on: 
Wednesday, February 28, 2024

Unique proprietary non-viral gene therapy platform with minimally invasive delivery technology providing long lasting gene expression and favorable distribution in the retina.

Key Points: 
  • Unique proprietary non-viral gene therapy platform with minimally invasive delivery technology providing long lasting gene expression and favorable distribution in the retina.
  • A substantially de-risked platform and two first-in-class gene therapies heading to the clinic, having the potential to become future blockbusters.
  • PARIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral gene therapies with minimally-invasive delivery technology, launches today with seed finance from Pureos Bioventures and ND Capital.
  • PulseSight is currently raising a Series A financing round to advance its programs into clinical proof-of-concept.

Cognition Therapeutics CEO Issues Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024

PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024. The full text of the letter follows:

Key Points: 
  • PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024.
  • The full text of the letter follows:
    The year ahead holds great promise for Cognition Therapeutics.
  • As we work towards these important milestones, we take stock of the achievements that give rise to optimism at Cognition Therapeutics and in the broader medical community.
  • For Cognition, expanding the pipeline for CT1812 to dry AMD has the potential to grow Cognition’s value across multiple age-related diseases.

Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment

Retrieved on: 
Tuesday, October 24, 2023

The U.S. Food and Drug Administration (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application, opening the door to a groundbreaking clinical investigation of EA 2351.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application, opening the door to a groundbreaking clinical investigation of EA 2351.
  • This innovative compound offers hope to patients battling geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD).
  • Endogena Therapeutics remains dedicated to its mission of unlocking the body's regenerative potential and making a meaningful impact on patients' lives.
  • This latest achievement reinforces the company's commitment to advancing innovative therapies for conditions that urgently require novel treatment options.

Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells

Retrieved on: 
Wednesday, October 11, 2023

11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells”.

Key Points: 
  • 11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells”.
  • The patent, which has been exclusively licensed to Lineage, has an expected expiration date of July 28, 2036.
  • Subretinal delivery of OpRegen has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.
  • The program is being developed under an exclusive worldwide collaboration between Lineage, Roche , and Genentech , a member of the Roche Group.

Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

Retrieved on: 
Wednesday, May 24, 2023

Patients in the pooled treatment group showed a 59% reduction in risk of >15-letter loss (n=181, p=0.008).

Key Points: 
  • Patients in the pooled treatment group showed a 59% reduction in risk of >15-letter loss (n=181, p=0.008).
  • The primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance.
  • The totality of the data on ANX007 from the ARCHER trial are promising, with the demonstrated preservation of functional vision in GA patients, regardless of their lesion location or size.
  • Preclinical models have demonstrated that inhibition of C1q protects photoreceptor cell synapses, and importantly, photoreceptor cell function.

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Retrieved on: 
Wednesday, April 26, 2023

RG6501 (OpRegen) is an allogeneic retinal pigment epithelial (RPE) cell therapy currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Key Points: 
  • RG6501 (OpRegen) is an allogeneic retinal pigment epithelial (RPE) cell therapy currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • Long term vision preservation with outer retinal structure improvement observed in the OpRegen treated eye persisted for up to 4 years of follow-up.
  • Further assessment of the optimal disease stage for intervention and target delivery location of OpRegen in a larger clinical study is needed to confirm these preliminary findings.
  • A Phase 2a study evaluating the success of OpRegen delivery to target areas of GA is currently enrolling patients (ClinicalTrials.gov: NCT05626114).

Luxa Biotechnology to Provide Update on Clinical Trial of Retinal Pigmented Epithelium Stem Cell (RPESC) Technology for Treatment of Dry Age-Related Macular Degeneration in Panel Session at ARVO 2023

Retrieved on: 
Thursday, April 20, 2023

The panel session will take place on April 24 at 10am CT in the exhibitor’s presentation area in the ARVO exhibit hall at the Ernest N. Morial Convention Center.

Key Points: 
  • The panel session will take place on April 24 at 10am CT in the exhibitor’s presentation area in the ARVO exhibit hall at the Ernest N. Morial Convention Center.
  • RPESC-RPE-4W is derived from an adult retinal pigmented epithelium stem cell (RPESC) that produces retinal pigmented epithelium (RPE) cell progeny.
  • The cell product being used in the clinical trial is a progenitor stage RPESC-RPE obtained after 4 weeks of differentiation (RPESC-RPE-4W).
  • Transplanted RPESC-RPE-4W provided durable preservation of RPE cell functions and supported overlying photoreceptor cells resulting in sustained vision rescue.

Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023

Retrieved on: 
Wednesday, April 19, 2023

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting in vitro results characterizing the role of sigma-2 (σ-2) receptors and effect of CT1812 in cell-based models of dry age-related macular degeneration (AMD).

Key Points: 
  • NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting in vitro results characterizing the role of sigma-2 (σ-2) receptors and effect of CT1812 in cell-based models of dry age-related macular degeneration (AMD).
  • CT1812 is an experimental orally delivered, small molecule drug candidate that binds to σ-2 receptors, which have been shown to regulate key cellular processes involved in age-related degenerative diseases.
  • Biological pathways impacted by disease-relevant stressors in RPE cells were identified, some of which were also modulated by CT1812.
  • Pathways that were impacted by CT1812 include those involved in immune response, extracellular matrix remodeling and RPE cell survival.